Advertisement

Maternal Use of Drugs for Thyroid Disease and Infant Congenital Malformations

  • Bengt Källén
Chapter

Abstract

Use of thyroxine substitution at hypothyroidism seems not to be associated with any major teratogenic risk—the effects which have been found seem to be explained by concomitant drug use.

Use of propylthiouracil at hyperthyroidism is probably not associated with a major malformation risk. Suggested effects on specific, mainly less severe, malformations are based on low numbers and different studies identified different malformations in excess. Probably propylthiouracil has a low if any teratogenic potential, and it may be the drug of choice in early pregnancy. Methimazole and related drugs are linked to a specific constellation of malformations, notably scalp defects, choanal atresia, esophageal atresia, and omphalocele. The risk for these malformations is much increased, resulting in an about doubling of the risk of any major malformation. If possible, this drug should be avoided in early pregnancy. If it has been used, prenatal diagnosis may at least be able to identify omphalocele early enough to permit an interruption of pregnancy.

References

  1. Andersen SL, Olsen J, Wu CS, Laurberg P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab. 2013;98:4373–81.CrossRefGoogle Scholar
  2. Andersen SL, Olsen J, WU CS, Laurberg P. Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid. 2014;24:1533–40.CrossRefGoogle Scholar
  3. Clementi M, Di Gianantonio E, Pelo E, Mammi I, Basile RT, Tenconi R. Methimazole embryopathy: delineation of the phenotype. Am J Med Genet. 1999;83:43–6.CrossRefGoogle Scholar
  4. Clementi M, DiGianantonio E, Cassina M, Leoncini E, Botto LO, Mastrioacovo P. Treatment of hyperthyroidism in pregnancy and birth defects. J Clin Endocrinol Metab. 2010;95:E337–41.CrossRefGoogle Scholar
  5. DiGianantonio E, Schaefer C, Mastroiacovo P, Cournot MP, Benedicenti F, Reuvers M, Occupati B, Robert E, Bellemin B, Addis A, Amon J, Clementi M. Adverse effects of prenatal methimazole exposure. Teratology. 2001;64:262–6.CrossRefGoogle Scholar
  6. Ferraris S, Valenzise M, Lerone M, Divizia MT, Rosaia L, Blaid D, Nemelka O, Ferrero GB, Silengo M. Malformations following methimiazole exposure in utero: an open issue. Birth Defects Res A Clin Mol Teratol. 2003;67:989–92.CrossRefGoogle Scholar
  7. Heinonen OP, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton, MA: Publishing Sciences Group; 1977.Google Scholar
  8. Källén B, Norstedt Wikner B. Maternal hypothyroidism in early pregnancy and infant structural malformations. J Thyroid Res. 2014;2014:160780.  https://doi.org/10.1144/2014/160780.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Khoury MJ, Becerra JE, d’Almada PJ. Maternal thyroid disease and risk or birth defects in offspring: a population-based case-control study. Paediatr Perinat Epidemiol. 1989;3:402–20.CrossRefGoogle Scholar
  10. Milham S, Elledge W. Maternal methimazole and congenital defects in children. Teratology. 1972;5:125.CrossRefGoogle Scholar
  11. Mujtaba Q, Burrow GN. Treatment of hyperthyroidism in pregnancy with propylthiouracil and methimazole. Obstet Gynecol. 1975;46:282–6.PubMedGoogle Scholar
  12. Norstedt Wikner B, Skjöldebrand Sparre L, Stiller C-O, Källén B, Asker C. Maternal use of thyroid hormones in pregnancy and neonatal outcome. Acta Obstet Gynecol Scand. 2008;87:617–27.CrossRefGoogle Scholar
  13. Ordóñes MP, Nazer J, Aguilla A, Cifuentes L. Malformaciones congénitass y patologia crónica de la madre. Estudio ECLAMC 1971–1999. Rev Méd Chile. 2003;131:404–11.Google Scholar
  14. Schumann L, Hansen AV, Garne E. Pregnancy outcomes after fetal exposure to antithyroid medications or levothyroxine. Early Hum Dev. 2016;101:73–7.CrossRefGoogle Scholar
  15. Su P-Y, Huang K, Hao J-H, Xu Y-Q, Yan S-Q, Li T, Xu Y-H, Tao F-B. Maternal thyroid function in the first twenty weeks of pregnancy and subsequent fetal and infant development: a prospective population-based cohort study in China. J Clin Endocrinol Metab. 2011;96:3234–41.CrossRefGoogle Scholar
  16. Yoshihara A, Noh JY, Yamaguchi T, Ohye H, Sato S, Sekiya Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K. Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab. 2012;97:2396–403.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Bengt Källén
    • 1
  1. 1.Tornblad Institute for Comparative EmbryologyLund UniversityLundSweden

Personalised recommendations